

**INSTITUTIONAL ETHICS COMMITTEE
YASHODA ACADEMY OF MEDICAL EDUCATION AND RESEARCH
(IEC-YAMER)**

Yashoda Hospital, Behind Harihara Kala Bhavan, Secunderabad- 500003 (T.S)

Reg.No.ECR/49/Inst/AP/2013/RR-19

Chairman: Justice V.BHASKAR RAO
(Retd.) Judge, High Court of A.P

Member: Dr.I.DINAKAR
Consultant Neuro Surgeon,
Yashoda Hospital, Secunderabad

Member: Dr.S.MANIMALA RAO,
Secretary Chief Anesthesiologist & Intensivist,
Yashoda Hospital, Somajiguda, Hyderabad

Member: Sri. S.A.DANIEL
Chief Operating Officer,
Joyce Meyer Ministries, Nanakramguda, Hyd.

Member: Dr. B. SESI KERAN
Former Director,
National Institute of Nutrition (ICMR)
Hyderabad.

Member: Dr.P.NAVANITH SAGAR REDDY
Sr.Consultant Pulmonologist,
Yashoda Hospital, Somajiguda, Hyderabad.
Retd.Prof. & Head Dept. of Pulmonary Medicine,
Osmania Medical College, Hyderabad

Member: Dr. D.GOVINDA DAS
Retd. Professor of Clinical Pharmacology
Osmania Medical College, Hyderabad

Member: Sri.L.HANUMANTH RAO
Hony.Vive-President,
Indian Red Cross Society, A.P.
Hyderabad.

Member: Dr.(Mrs.) MEENA HARIHARAN
Director,
Center for Health Psychology.
University of Hyderabad

Joint: Dr.BVCS.SRINIVASARAO
Secretary Research Coordinator,
Yashoda Group of Hospitals, Hyderabad.

DC/PP-01/2021

Permission letter

05th April 2021

To
Dr.Pankaj Jariwala,
Consultant Interventioanl Cardiologist
Yashoda Hospital, Somajiguda, Hyderabad.

Sub: Permission letter "The Addition of Dapagliflozin, Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2I) to Angiotensin Receptor Blocker-Nepriylsin Inhibitors [ARNI] Non-Responders in patient with Refractory Heart Failure with Reduced Ejection Fraction [HFREF]. (ADD DAPA TRIAL) "

Ref: Your letter dated 05th April 2021


Dear Sir,

The IEC-YAMER has given permission to do the study at Yashoda Hosptial, Somajiguda, Hyderabad
Title "The Addition of Dapagliflozin, Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2I) to Angiotensin Receptor Blocker-Nepriylsin Inhibitors [ARNI] Non-Responders in patient with Refractory Heart Failure with Reduced Ejection Fraction [HFREF]. (ADD DAPA TRIAL) "

This study was Retrospective hence Informed Consent waved off.



Yours Sincerely


Dr.BVCS.Srinivasarao,
Joint Secretary-IEC-YAMER,
Yashoda Group of Hospital, Hyderabad.

**INSTITUTIONAL ETHICS COMMITTEE
YASHODA ACADEMY OF MEDICAL EDUCATION AND RESEARCH
(IEC-YAMER)**

Yashoda Hospital, Behind Harihara Kala Bhavan, Secunderabad- 500003 (T.S)
Reg.No.ECR/49/Inst/AP/2013/RR-19

Chairman: Justice V.BHASKAR RAO
(Retd.) Judge, High Court of A.P

Member: Dr.I.DINAKAR
Consultant Neuro Surgeon,
Yashoda Hospital, Secunderabad

Member: Dr.S.MANIMALA RAO,
Secretary Chief Anesthesiologist & Intensivist,
Yashoda Hospital, Somajiguda, Hyderabad

Member: Sri. S.A.DANIEL
Chief Operating Officer,
Joyce Meyer Ministries, Nanakramguda, Hyd.

Member: Dr. B. SESI KERAN
Former Director,
National Institute of Nutrition (ICMR)
Hyderabad.

Member: Dr.P.NAVANITH SAGAR REDDY
Sr.Consultant Pulmonologist,
Yashoda Hospital, Somajiguda, Hyderabad.
Retd.Prof. & Head Dept. of Pulmonary Medicine,
Osmania Medical College, Hyderabad

Member: Dr. D.GOVINDA DAS
Retd. Professor of Clinical Pharmacology
Osmania Medical College, Hyderabad

Member: Sri.L.HANUMANTH RAO
Hony.Vive-President,
Indian Red Cross Society, A.P.
Hyderabad.

Member: Dr.(Mrs.) MEENA HARIHARAN
Director,
Center for Health Psychology.
University of Hyderabad

Joint: Dr.BVCS.SRINIVASARAO
Secretary Research Coordinator,
Yashoda Group of Hospitals, Hyderabad.

DC/PP-01/2021

Permission letter

05th April 2021

To
Dr.Pankaj Jariwala,
Consultant Interventional Cardiologist
Yashoda Hospital, Somajiguda, Hyderabad.

Sub: Permission letter "The Addition of Dapagliflozin, Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2I) to Angiotensin Receptor Blocker-Nepriylsin Inhibitors [ARNI] Non-Responders in patient with Refractory Heart Failure with Reduced Ejection Fraction [HFREF]. (ADD DAPA TRIAL) "

Ref: Your letter dated 05th April 2021


Dear Sir,

The IEC-YAMER has given permission to do the study at Yashoda Hospital, Somajiguda, Hyderabad
Title "The Addition of Dapagliflozin, Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT2I) to Angiotensin Receptor Blocker-Nepriylsin Inhibitors [ARNI] Non-Responders in patient with Refractory Heart Failure with Reduced Ejection Fraction [HFREF]. (ADD DAPA TRIAL) "

This study was Retrospective hence Informed Consent waved off.



Yours Sincerely


Dr.BVCS.Srinivasarao,
Joint Secretary-IEC-YAMER,
Yashoda Group of Hospital, Hyderabad.